Bristol Myers Squibb's Q4 2025 earnings call spotlighted key milestones for the Opdualag franchise in melanoma 📊 Blockbuster Status and US Dominance Four years post-launch, Opdualag reached blockbuster status with 2025 global revenues of $1,185M, driven by $1,045M in the US. It has captured over 30% US market share, cementing its role as a standard-of-care option for metastatic melanoma. The ex-US market remains largely untapped with sales generating only $140M, constrained

⭐ Summit Therapeutics, Inc. has reportedly been in partnership discussions with AstraZeneca and other major pharma companies for its sole asset, Ivonescimab (PD-1xVEGF BsAb) (Ref 1). ⭐ The potential deal, which could be valued at a staggering ~$15 billion (or higher?), would give a significant return on investment for Summit, which acquired the rights to ivonescimab from Akeso Biopharma in Dec 2022 in a transaction worth up to $5 billion, with a $500 million upfront payment (

📢 AbbVie is set to acquire University of Pennsylvania’s spinout, Capstan Therapeutics for up to $2.1 billion in cash, representing one of the major acquisitions in the CGT space in 2025. ⭐ The acquisition price represents a significant premium over Capstan's last valuation, however, with this deal AbbVie gains full access to Capstan's key programs and most importantly its proprietary in vivo cell engineering technology, which was developed by the world-renowned scientists. ⭐

🤝 Bristol Myers Squibb is set to acquire 2seventy bio in an all-cash transaction valued at approximately $286 million. After accounting for 2seventy bio’s cash reserves, the net acquisition cost for BMS stands at around $102 million. The deal is expected to close in H2'25. 👉 This acquisition gives BMS full control of Abecma (idecabtagene vicleucel), a BCMA-targeted CAR-T cell therapy indicated for the treatment of adult patients with R/R multiple myeloma after two or more p

📢 The U.S. FDA launched a new program - the Commissioner’s National Priority Voucher (CNPV) - to shorten review timelines from 10-12 months to 1-2 months following a sponsor’s final drug application submission. ⭐ The vouchers will be given only to the companies that are aligned with U.S. national priorities. ⭐ Attached is the slide deck with additional details. 📧 For further details, please write to us at support@oncofocus.com. 🌐 References: 1) https://www.fda.gov/news-eve

⭐ BioNTech SE and Bristol Myers Squibb entered into a global strategic partnership with a 50/50 profit/loss split to co-develop and co-commercialize BNT327 (PD-L1xVEGF-A BsAb) across numerous solid tumor types (Ref 1). ⭐ BMS will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. ⭐ In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial mile

“The right target, at the right time, for the right price” …is and always has been a guiding principle for Merck KGaA, as stated by its CEO, Belen Garijo. It appears that Merck KGaA has now identified the ‘right’ acquisition target - SpringWorks Therapeutics. As reported by Reuters, Merck KGaA is in advanced talks to acquire the US-based cancer and rare disease biotech SpringWorks. The potential deal, which could be finalized in the coming weeks, is expected to expand Merck’

The first-line metastatic Melanoma market is currently dominated by immune checkpoint inhibitors—BMS' Opdivo + Yervoy, Opdualag, Opdivo, and Merck/MSD's Keytruda. Other treatment options include BRAF/MEK inhibitors (for BRAF+ve pts). Currently, Opdivo + Yervoy is considered as the gold standard with an mOS of 71.9 months; however, it is associated with a high rate of Gr 3/4 TRAEs (62.6%). BMS' Opdualag, a combination of anti-LAG-3 (relatlimab) + anti-PD-1 (nivolumab), entered

Bladder cancer is the most common malignancy of the urinary tract. As of 2022, Bladder Cancer had an incidence of 614,298 patients worldwide, and 220,596 patients succumbed to the disease. While the therapeutic approach to it remained largely unchanged for many years, recent clinical progress has paved the way towards a novel era of diagnosis and management of the disease, with several special designations and two very recent approvals by the US FDA. In December 2023, the FD

Esophageal cancer is the fourteenth most commonly diagnosed cancer and the eighth leading cause of cancer-related death worldwide. The burden of esophageal cancer incidence and mortality is steadily increasing worldwide due to increased prevalence of associated risk factors such as tobacco and alcohol consumption, poor diet, sedentary lifestyle and obesity. Despite advancements in targeted therapies and immunotherapies, the prognosis of Esophageal cancer remains dismal, with

CAR-T therapy has dramatically changed the course of cancer management over the past few years. However, despite this impact, one of the key challenges about the CAR-T therapies is its highly complex and long manufacturing process. With this lengthy manufacturing time and long wait-time, patients face higher chance of disease progression. To address this scenario, many novel platforms which promote rapid production of CAR-Ts are underway. Several steps utilized in conventiona

Renal cell carcinoma (RCC) stands as the predominant form of kidney cancer, comprising about 90% of kidney cancer cases. It accounts for roughly 3% of all cancer diagnoses, with a notably higher occurrence in Western countries, likely linked to the increased detection of small renal masses. Despite advancements in targeted therapies and immunotherapies, the prognosis for stage IV RCC remains challenging, with a 5-year survival rate of only 17%. Furthermore, non-clear cell RCC

Cervical cancer ranks as the second most common feminine malignant tumor and the second leading cause of death among female cancers worldwide. Nearly 99% of cervical cancer cases are linked to HPV infection, making it largely preventable through HPV vaccination. Despite this, there were 604,127 new global cases and 341,831 deaths in 2020. Localized cervical cancer, which accounts for about 43% of all cases, has a five-year relative survival rate of 91.2%. However, locally adv

PD-(L)1 axis inhibits CAR-T cell activation, proliferation, survival, and functionality. Thus, CAR-T mediated direct targeting of the PD-(L)1 immunosuppressive axis or modulation of the axis along with CAR-T therapy holds a huge promise to unleash the full potential of CAR-Ts. Multiple strategies are under investigation to target PD-(L)1 immunosuppressive axis to increase CAR-T therapy efficacy. We have grouped the strategies under the following three broad categories, Combin

Acute myeloid leukemia (AML) is the most common type of leukemia among the adult population and accounts for about 80% of all cases. Despite development of novel treatment options and targeted therapeutics, the 5-year survival rate in adult population is quite low, indicating towards a huge unmet need in AML treatment space. The current infographic concisely highlights the key treatment options for AML and some of the emerging therapeutic stratagems.

Gastric cancer has remained one of the leading causes of cancer-related deaths globally. It was reported as the 5th most common cancer and the 4th leading cause of cancer death worldwide in 2020, with an observed trend of increasing incidence rates in younger adults (<50 years). Despite therapeutic progress, the survival rate for gastric cancer patients remains low, highlighting the unmet need for treatments of further potential. In this concise infographic, we highlight the

Breast cancer is the most commonly diagnosed cancer worldwide with a steady increase in incidence rate over the past decades. It is estimated that, if the current trends remain unchanged, the burden of breast cancer is set to grow to over 3 million new cases and 1 million deaths per year by 2040 as a result of population growth and ageing alone. The infographic highlights the current key options in Breast cancer's evolving treatment paradigm with a glimpse of the emerging the

Thyroid Cancer, despite a good prognosis, has been a cause of concern over the past years. Thyroid Cancer shows no symptoms in the early stage, but its increasing rate of occurrence indicates the need for further diagnostic and therapeutic options. In observance of Thyroid Cancer Awareness month, Oncofocus is pleased to present an infographic highlighting the key options with a glimpse of the emerging therapies in the Thyroid cancer treatment paradigm.

In observance of Sarcoma Awareness Month, Oncofocus is pleased to present a user-friendly infographic. This comprehensive visual presentation aims to elucidate crucial aspects such as epidemiology, key treatment options, and emerging therapies related to sarcoma. By staying informed and actively participating in sharing this publicly accessible infographic, we can collectively raise awareness about sarcoma and its implications. Together, let us make a positive impact during S

In acknowledgment of Melanoma Awareness Month, Oncofocus presents a user-friendly infographic. It showcases a glimpse into top-level epidemiology data, key treatment options, and emerging therapies. Stay informed and help spread melanoma awareness with this publicly accessible infographic.